Marion McCourt; Executive Vice President - Commercial; Regeneron Pharmaceuticals Inc. Christopher Fenimore; Chief Financial Officer, Senior Vice President - Finance; Regeneron Pha ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

which are ideal for extracellular targets and those on the cell surface,” said George Yancopoulos, president and chief scientific officer of Regeneron. “Through the RGC and our other research ...

When the GPR75 researh was published, Regeneron's chief scientific officer George Yancopoulos, described the mutations as a "genetic superpower" that "provides hope in combating global health ...

in earlier lines of therapy," said Regeneron's chief scientific officer George Yancopoulos. "We're also excited to be advancing our broader pipeline of CD3 and other bispecific therapies ...

as well as enable new approaches to healthcare analytics and healthcare management," remarked Regeneron's chief scientific officer, George Yancopoulos.

George Yancopoulos. “These results also validate the role type 2 inflammation plays in driving COPD in these patients, advancing the scientific community’s understanding of the underlying biol ...

Regeneron hosted a celebration to recognize the achievements of the 17 students selected as the Westchester 2025 Regeneron Science Talent Search Scholars. Beginning in 1942, the contest […] ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

George D. Yancopoulos, president and chief scientific officer of Regeneron, said: "NASH is a major cause of death in this country, with no current treatment options. We're eager to build on the ...

Yancopoulos, president and chief scientific officer at Regeneron, said in statement. "This latest approval represents an important next chapter for Dupixent, giving those with COPD a novel option ...